Piper Jaffray Cuts Price Target on Antares Pharma (ATRS) Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Antares Pharma's (ATRS) CFO Resigns
August 11, 2016 7:15 AM EDTAntares Pharma (NASDAQ: ATRS) disclosed in an SEC filing:
On August 5, 2016, Antares Pharma, Inc. (the Company) received a written notice of resignation from James E. Fickenscher, the Companys Senior Vice President and Chief Financial Officer. Mr. Fickenschers resignation will become effective September 4, 2016.... More
Antares Pharma (ATRS) Reports In-Line Q2 EPS
August 9, 2016 7:50 AM EDTAntares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More